• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bayer Ag ADR (OP:BAYRY)

    11.76 +0.31 (+2.71%)
    Streaming Delayed Price Updated: 12:16 PM EDT, Apr 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Bayer Ag ADR

    < Previous 1 2 Next >
    News headline image
    Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential
    From Bayer
    Via Business Wire
    News headline image
    Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
    From Bayer
    Via Business Wire
    News headline image
    KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
    From Bayer
    Via Business Wire
    News headline image
    New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
    From Bayer
    Via Business Wire
    News headline image
    Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
    From Bayer
    Via Business Wire
    News headline image
    Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA
    From Bayer
    Via Business Wire
    News headline image
    Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
    From Bayer
    Via Business Wire
    News headline image
    Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
    From Bayer
    Via Business Wire
    News headline image
    Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
    From Bayer
    Via Business Wire
    News headline image
    Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
    From Bayer
    Via Business Wire
    News headline image
    Bayer Accelerates Pharma Growth on High-Value Portfolio
    From Bayer
    Via Business Wire
    News headline image
    Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause
    From Bayer
    Via Business Wire
    News headline image
    Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus
    From Bayer
    Via Business Wire
    News headline image
    Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
    From Bayer
    Via Business Wire
    News headline image
    Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference
    From Bayer
    Via Business Wire
    News headline image
    Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
    From Bayer
    Via Business Wire
    News headline image
    RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
    From Bayer
    Via Business Wire
    News headline image
    Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
    From Bayer
    Via Business Wire
    News headline image
    U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
    From Bayer
    Via Business Wire
    News headline image
    Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
    From Bayer
    Via Business Wire
    News headline image
    KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
    From Bayer
    Via Business Wire
    News headline image
    Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
    From Bayer
    Via Business Wire
    News headline image
    Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
    From Bayer
    Via Business Wire
    News headline image
    Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
    From Bayer
    Via Business Wire
    News headline image
    One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
    From Bayer
    Via Business Wire
    News headline image
    BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
    From Bayer
    Via Business Wire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.